TBXT and myelodysplastic syndrome: In the future, further analysis of scRNA-seq data from more t-MDS and p-MDS BM samples hold the promise to elucidate how different cell types contribute to t-MDS progression after CAR T therapy, and provide directions to recognizing t-MN regulators and biomarkers for precision medicine and prognosis evaluation.